NASDAQ:ALLR Allarity Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.79 +0.03 (+1.70%) (As of 06/24/2022 04:00 PM ET) Add Compare Share Today's Range$1.76▼$1.8550-Day Range$1.11▼$2.9952-Week Range$1.10▼$18.20Volume59,329 shsAverage Volume266,463 shsMarket Capitalization$16.61 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALLR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allarity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLR Stock Forecast (MarketRank)Overall MarketRank™1.83 out of 5 starsMedical Sector757th out of 1,411 stocksPharmaceutical Preparations Industry368th out of 672 stocksAnalyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingAllarity Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Allarity Therapeutics has a forecasted upside of 346.9% from its current price of $1.79.Amount of Analyst CoverageAllarity Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Community Rank Outperform VotesAllarity Therapeutics has received 1 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAllarity Therapeutics has received 0 “underperform” votes. (Add your “underperform” vote.)Community SentimentAllarity Therapeutics has received 100.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Allarity Therapeutics and other stocks. Vote “Outperform” if you believe ALLR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALLR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAllarity Therapeutics does not currently pay a dividend.Dividend GrowthAllarity Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allarity Therapeutics insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Allarity Therapeutics are expected to grow in the coming year, from ($1.86) to ($1.02) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Allarity Therapeutics (NASDAQ:ALLR)Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.Read More ALLR Stock News HeadlinesMay 29, 2022 | benzinga.comAllarity Therapeutics (NASDAQ:ALLR), Earnings Estimates, EPS, and RevenueMay 29, 2022 | seekingalpha.comAllarity Therapeutics GAAP EPS of -$0.56May 27, 2022 | finance.yahoo.comAllarity Therapeutics Reports First Quarter 2022 Financial ResultsMay 26, 2022 | seekingalpha.comAllarity, Better Therapeutics top healthcare gainers; INmune Bio, Liquidia lead losers' packMay 26, 2022 | investing.comAllarity Therapeutics Inc (ALLR)May 21, 2022 | barrons.comAllarity Therapeutics Inc.May 18, 2022 | finance.yahoo.comCorrection Notice to Press Release Announcing Financial Results For the Fourth Quarter and Full Year 2021 Financial Results and Corporate UpdateMay 17, 2022 | seekingalpha.comAllarity Therapeutics reports Q4 resultsMay 16, 2022 | finance.yahoo.comAllarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate UpdateSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALLR CUSIPN/A CIK1860657 Webwww.allarity.com Phone401-426-4664FaxN/AEmployees14Year FoundedN/ACompany Calendar Today6/26/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$8.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+346.9%Consensus RatingBuy Rating Score (0-4)3 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares9,280,000Free FloatN/AMarket Cap$16.61 million OptionableNot Optionable BetaN/A Allarity Therapeutics Frequently Asked Questions Should I buy or sell Allarity Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allarity Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Allarity Therapeutics stock. View analyst ratings for Allarity Therapeutics or view top-rated stocks. What is Allarity Therapeutics' stock price forecast for 2022? 1 Wall Street research analysts have issued twelve-month price targets for Allarity Therapeutics' shares. Their ALLR stock forecasts range from $8.00 to $8.00. On average, they predict Allarity Therapeutics' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 346.9% from the stock's current price. View analysts' price targets for Allarity Therapeutics or view top-rated stocks among Wall Street analysts. How has Allarity Therapeutics' stock performed in 2022? Allarity Therapeutics' stock was trading at $10.75 at the start of the year. Since then, ALLR shares have decreased by 83.3% and is now trading at $1.79. View the best growth stocks for 2022 here. Who are Allarity Therapeutics' key executives? Allarity Therapeutics' management team includes the following people: Mr. Stefano R. Carchedi, CEO, Pres & Director (Age 60, Pay $669.58k)Mr. Jens Erik Knudsen CPA, M.B.A., Chief Financial Officer (Age 53, Pay $333.62k)Mr. James G. Cullem J.D., Sr. VP of Corp. Devel. (Age 52, Pay $356.85k)Dr. Marie Foegh DrSc, M.D., Chief Medical Officer (Age 78, Pay $424.08k)Mr. Peter Buhl Jensen Adj Professor, M.D., M.D., Ph.D., Ph.D., Co-Founder (Age 67)Dr. Steen Meier Knudsen Ph.D., Founder & Chief Scientific Officer (Age 61)Ms. Ulla Hald Buhl, Founder, COO, Chief IR & Communications (Age 58)Mr. Thomas H. Jensen, Founder & Sr. VP of Information Technologies (Age 44)Mr. Claus Frisenberg Pedersen, Chief Commercial Officer (Age 50)Ms. Annie Rasmussen, Chief of Clinical Operations (Age 65) Who are some of Allarity Therapeutics' key competitors? Some companies that are related to Allarity Therapeutics include Xilio Therapeutics (XLO), Infinity Pharmaceuticals (INFI), PLx Pharma (PLXP), BioLineRx (BLRX), Opiant Pharmaceuticals (OPNT), Athersys (ATHX), NightHawk Biosciences (NHWK), Sensei Biotherapeutics (SNSE), eFFECTOR Therapeutics (EFTR), Orgenesis (ORGS), Decibel Therapeutics (DBTX), Lumos Pharma (LUMO), Eyenovia (EYEN), IMV (IMV) and LifeVantage (LFVN). View all of ALLR's competitors. What is Allarity Therapeutics' stock symbol? Allarity Therapeutics trades on the NASDAQ under the ticker symbol "ALLR." Who are Allarity Therapeutics' major shareholders? Allarity Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.00%). Which major investors are buying Allarity Therapeutics stock? ALLR stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. How do I buy shares of Allarity Therapeutics? Shares of ALLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Allarity Therapeutics' stock price today? One share of ALLR stock can currently be purchased for approximately $1.79. How much money does Allarity Therapeutics make? Allarity Therapeutics (NASDAQ:ALLR) has a market capitalization of $16.61 million. How many employees does Allarity Therapeutics have? Allarity Therapeutics employs 14 workers across the globe. How can I contact Allarity Therapeutics? The official website for Allarity Therapeutics is www.allarity.com. The company can be reached via phone at 401-426-4664. This page (NASDAQ:ALLR) was last updated on 6/26/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
